Publications by authors named "Elena Fare"

Claim this Profile
I
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group).
Melissa Bersanelli, Giulia Mazzaschi, Patrizia Giannatempo, Daniele Raggi, Elena Farè

Immunotherapy· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study.
Andrea Necchi, Daniele Raggi, Patrizia Giannatempo, Laura Marandino, Elena Farè

Eur Urol Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
Laura Marandino, Antonella Capozza, Marco Bandini, Daniele Raggi, Elena Farè

Eur Urol Focus· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, Marco Bandini, Giuseppe Luigi Banna

Clin Med Insights Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment.
Daniele Raggi, Marco Bandini, Patrizia Giannatempo, Elena Farè, Laura Marandino

Clin Genitourin Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab.
Laura Marandino, Antonella Capozza, Marco Bandini, Daniele Raggi, Elena Farè

Urol Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.
Marco Bandini, Jeffrey S Ross, Daniele Raggi, Andrea Gallina, Maurizio Colecchia

J Natl Cancer Inst· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
Andrea Necchi, Daniele Raggi, Andrea Gallina, Jeffrey S Ross, Elena Farè

Eur Urol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.
Andrea Necchi, Marco Bandini, Giuseppina Calareso, Daniele Raggi, Filippo Pederzoli

Eur Urol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
Andrea Necchi, Daniele Raggi, Andrea Gallina, Russell Madison, Maurizio Colecchia

Eur Urol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erdafitinib for the treatment of urothelial cancer.
Laura Marandino, Daniele Raggi, Patrizia Giannatempo, Elena Farè, Andrea Necchi

Expert Rev Anticancer Ther· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.
Claudio Vernieri, Michele Prisciandaro, Monica Milano, Maria Silvia Cona, Claudia Maggi

Clin Breast Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis.
Andrea Necchi, Patrizia Giannatempo, Daniele Raggi, Luigi Mariani, Maurizio Colecchia

Eur Urol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
Andrea Necchi, Andrea Anichini, Daniele Raggi, Alberto Briganti, Simona Massa

J Clin Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors.
Daniele Raggi, Patrizia Giannatempo, Rosalba Miceli, Elena Farè, Luigi Piva

Am J Clin Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings.
Nicola Nicolai, Laura Maria Sangalli, Andrea Necchi, Patrizia Giannatempo, Anna Maria Paganoni

Clin Genitourin Cancer· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life and pain control following laparoscopic retroperitoneal lymph node dissection in early-stage nonseminoma.
Nicola Nicolai, Elisabetta Bianchi, Ilaria Donati, Camilla L'Acqua, Cinzia Brunelli

Tumori· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
Andrea Necchi, Elena Farè, Salvatore Lo Vullo, Patrizia Giannatempo, Daniele Raggi

Clin Genitourin Cancer· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy.
Andrea Necchi, Patrizia Giannatempo, Biagio Paolini, Salvatore Lo Vullo, Manuela Marongiu

Clin Genitourin Cancer· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial design.
Andrea Necchi, Patrizia Giannatempo, Salvatore Lo Vullo, Elena Farè, Daniele Raggi

Clin Genitourin Cancer· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral center.
Andrea Necchi, Patrizia Giannatempo, Salvatore Lo Vullo, Elena Farè, Daniele Raggi

Clin Genitourin Cancer· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome in testicular sex cord stromal tumors: testis sparing vs. radical orchiectomy and management of advanced disease.
Nicola Nicolai, Andrea Necchi, Daniele Raggi, Davide Biasoni, Mario Catanzaro

Urology· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose chemotherapy for germ cell tumors: do we have a model?
Andrea Necchi, Francesco Lanza, Giovanni Rosti, Massimo Martino, Elena Farè

Expert Opin Biol Ther· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma.
Patrizia Giannatempo, Alessandra Alessi, Rosalba Miceli, Daniele Raggi, Elena Farè

Clin Genitourin Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
Andrea Necchi, Luigi Mariani, Patrizia Giannatempo, Daniele Raggi, Elena Farè

Clin Genitourin Cancer· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis